AUS
NZ
UK
CA
USA
IND
Proteomics International Laboratories Ltd (ASX:PIQ), a Perth-based medical technology firm focused on precision diagnostics and proteomics, has announced that its registered office address changed effective 2 July 2026. The new registered address is now at the Harry Perkins Institute of Medical Research, 6 Verdun Street, Nedlands, Western Australia 6009. This update was made in compliance with ASX Listing Rule 3.14, which mandates listed companies to report any registered office changes to the exchange. Market participants in the precision diagnostics sector may watch closely to determine if this relocation signals any broader strategic or operational shifts for the company.<\/p> <\/div>
Key Points<\/h3>
- Company: Proteomics International Laboratories Ltd (ASX:PIQ), part of the PILL Group<\/li>
- Registered office address updated effective 2 July 2026, per ASX Listing Rule 3.14 requirements<\/li>
- New registered office: Harry Perkins Institute of Medical Research, 6 Verdun Street, Nedlands, WA 6009<\/li>
- No financial data, operational guidance, or strategic changes accompanied the announcement<\/li>
- Investors should monitor for further updates clarifying if the move relates to operational or research developments<\/li>
<\/ul>
<\/div>
Proteomics International Relocates Registered Office to Harry Perkins Institute of Medical Research<\/h2>
Proteomics International Laboratories Ltd has formally informed the market that its registered office has shifted to the Harry Perkins Institute of Medical Research at 6 Verdun Street, Nedlands, Western Australia 6009. The change took effect on 2 July 2026 and was disclosed in adherence to ASX Listing Rule 3.14, which requires listed entities to promptly notify the ASX of any registered office address changes.<\/p>
The Harry Perkins Institute is a leading biomedical research centre within the QEII Medical Centre precinct in Nedlands, known for its extensive work across various medical research fields. The relocation of PIQ's registered office to this site may be of interest to investors tracking the company’s integration with research infrastructure. The company did not specify whether any operational departments, laboratories, or personnel have relocated as part of this change.<\/p>
Obligations Under ASX Listing Rule 3.14 for PIQ and Other Listed Companies<\/h2>
ASX Listing Rule 3.14 mandates that all listed companies immediately inform the ASX of any change to their registered office address. This administrative requirement applies universally across all sectors and company sizes on the Australian Securities Exchange, ensuring shareholders, regulators, and other Stakeholders<\/a> have access to current contact details.<\/p>
The notification from Proteomics International is a routine administrative update, authorised by the company’s board in line with continuous disclosure obligations. The announcement did not indicate any financial impact, restructuring, or changes to Business<\/a> operations linked to this address change. Investors seeking clarity on any operational implications are advised to contact the company directly through the provided channels.<\/p>
Proteomics International’s Specialisation in Precision Diagnostics and Proteomics<\/h2>
Proteomics International Laboratories Ltd identifies itself as a pioneer in precision diagnostics and bio-analytical services. Operating as a Subsidiary<\/a>\/">Wholly Owned Subsidiary<\/a> within the PILL Group, the company focuses on proteomics — described as the large-scale study of protein structures and functions. This field bridges molecular biology and clinical medicine, with applications in disease detection, biomarker discovery, and personalised treatment approaches.<\/p>
The company’s mission is to enhance lives by developing innovative tools that improve disease treatment. Headquartered in Perth, Western Australia, Proteomics International operates within the medical technology sector. The announcement did not provide updates on current research projects, partnerships, regulatory status, or financial performance.<\/p>
Maintaining Presence in the Nedlands, Western Australia Research Hub<\/h2>
Nedlands hosts several prominent medical and scientific institutions, including the University of Western Australia and the QEII Medical Centre campus. The Harry Perkins Institute, now the registered office location for PIQ, is part of this research cluster. The company’s previous registered address, Box 3008, Broadway, Nedlands, WA 6009, was also situated in the same suburb, indicating continuity in its geographic and scientific community presence.<\/p>
While the registered office primarily serves administrative and legal purposes rather than daily operations, the choice of the Harry Perkins Institute as the new address may be notable given its status as a leading biomedical research centre. The company did not disclose whether this move reflects any formal partnership or arrangement with the institute.<\/p>
Board Approval and Governance for the Registered Office Update<\/h2>
The announcement was authorised by the Board of Proteomics International Laboratories Ltd, consistent with standard ASX continuous disclosure protocols. This board-level approval confirms the registered office change adhered to internal governance procedures and was treated as a formal corporate matter prior to public release.<\/p>
The release included contact details for Dr James Williams, Chairman, and Mr David Morris, CEO and Managing Director, both reachable via the company’s general enquiry lines or email addresses listed. No direct commentary or quotes from executives were included.<\/p>
No Financial or Operational Guidance Provided with the Office Move<\/h2>
The company did not disclose any financial figures, cost estimates, or guidance related to the registered office relocation. There was no mention of Capital Expenditure<\/a>, nor details on changes to rental, Lease<\/a>, or occupancy arrangements. It is important to note that registered office addresses differ from principal places of business, so this change does not necessarily indicate a shift in primary operations or laboratory locations.<\/p>
No information on Revenue<\/a>, Earnings<\/a>, or forward-looking financial guidance accompanied this update. Investors should refer to the company’s latest financial reports, presentations, or separate announcements for insights into PIQ’s financial and commercial status.<\/p>
Relationship Between PIQ and the PILL Group Structure<\/h2>
Proteomics International Laboratories Ltd (ASX:PIQ) is the listed parent entity within the PILL Group. Proteomics International operates as a wholly owned subsidiary and trading name of PIQ. This corporate structure means the registered office change applies to the ASX-listed entity, Proteomics International Laboratories Ltd, which acts as the Holding Company<\/a>.<\/p>
This dual structure — with PIQ as the listed entity and Proteomics International as the operating subsidiary — is common in the medical technology sector. Investors and analysts should note that regulatory disclosures and investor communications are issued under the PIQ ticker, while operational activities and branding may use the Proteomics International name.<\/p>
Share Price Impact and Investor Outlook Following the Address Change<\/h2>
The immediate effect on PIQ’s share price was not evident from public data. Registered office address changes are typically administrative and not market-moving events, so this update alone is unlikely to significantly affect investor sentiment or trading volumes. Such disclosures are routine and generally do not trigger material share price fluctuations.<\/p>
Investors focused on PIQ’s progress in precision diagnostics and proteomics may find this update of limited immediate impact on their Investment<\/a> thesis. Key upcoming milestones for PIQ investors will likely relate to clinical advancements, commercial deals, revenue growth, or regulatory approvals in the company’s diagnostics pipeline, none of which were mentioned in this notice.<\/p>
Potential Implications of the Move to 6 Verdun Street for PIQ’s Operations<\/h2>
Although the company has not explicitly connected the registered office change to any strategic initiatives, relocating the registered address to the Harry Perkins Institute of Medical Research aligns with a medical technology company’s interest in proximity to leading biomedical research infrastructure. The institute is involved in diverse disease research programs and is situated within the Nedlands precinct, close to academic and clinical partners.<\/p>
This announcement indicates that PIQ remains embedded in the same geographic and scientific environment where it has operated. Investors may watch for future disclosures clarifying whether this move accompanies new research collaborations, Facility<\/a> agreements, or operational changes. No such details were provided in the current release.<\/p>
Proteomics International Relocates Registered Office to Harry Perkins Institute of Medical Research<\/h2>
Proteomics International Laboratories Ltd has formally informed the market that its registered office has shifted to the Harry Perkins Institute of Medical Research at 6 Verdun Street, Nedlands, Western Australia 6009. The change took effect on 2 July 2026 and was disclosed in adherence to ASX Listing Rule 3.14, which requires listed entities to promptly notify the ASX of any registered office address changes.<\/p>
The Harry Perkins Institute is a leading biomedical research centre within the QEII Medical Centre precinct in Nedlands, known for its extensive work across various medical research fields. The relocation of PIQ's registered office to this site may be of interest to investors tracking the company’s integration with research infrastructure. The company did not specify whether any operational departments, laboratories, or personnel have relocated as part of this change.<\/p>
Obligations Under ASX Listing Rule 3.14 for PIQ and Other Listed Companies<\/h2>
ASX Listing Rule 3.14 mandates that all listed companies immediately inform the ASX of any change to their registered office address. This administrative requirement applies universally across all sectors and company sizes on the Australian Securities Exchange, ensuring shareholders, regulators, and other Stakeholders<\/a> have access to current contact details.<\/p>
The notification from Proteomics International is a routine administrative update, authorised by the company’s board in line with continuous disclosure obligations. The announcement did not indicate any financial impact, restructuring, or changes to Business<\/a> operations linked to this address change. Investors seeking clarity on any operational implications are advised to contact the company directly through the provided channels.<\/p>
Proteomics International Laboratories Ltd identifies itself as a pioneer in precision diagnostics and bio-analytical services. Operating as a Subsidiary<\/a>\/">Wholly Owned Subsidiary<\/a> within the PILL Group, the company focuses on proteomics — described as the large-scale study of protein structures and functions. This field bridges molecular biology and clinical medicine, with applications in disease detection, biomarker discovery, and personalised treatment approaches.<\/p>
The company’s mission is to enhance lives by developing innovative tools that improve disease treatment. Headquartered in Perth, Western Australia, Proteomics International operates within the medical technology sector. The announcement did not provide updates on current research projects, partnerships, regulatory status, or financial performance.<\/p>
Nedlands hosts several prominent medical and scientific institutions, including the University of Western Australia and the QEII Medical Centre campus. The Harry Perkins Institute, now the registered office location for PIQ, is part of this research cluster. The company’s previous registered address, Box 3008, Broadway, Nedlands, WA 6009, was also situated in the same suburb, indicating continuity in its geographic and scientific community presence.<\/p>
While the registered office primarily serves administrative and legal purposes rather than daily operations, the choice of the Harry Perkins Institute as the new address may be notable given its status as a leading biomedical research centre. The company did not disclose whether this move reflects any formal partnership or arrangement with the institute.<\/p>
The announcement was authorised by the Board of Proteomics International Laboratories Ltd, consistent with standard ASX continuous disclosure protocols. This board-level approval confirms the registered office change adhered to internal governance procedures and was treated as a formal corporate matter prior to public release.<\/p>
The release included contact details for Dr James Williams, Chairman, and Mr David Morris, CEO and Managing Director, both reachable via the company’s general enquiry lines or email addresses listed. No direct commentary or quotes from executives were included.<\/p>
The company did not disclose any financial figures, cost estimates, or guidance related to the registered office relocation. There was no mention of Capital Expenditure<\/a>, nor details on changes to rental, Lease<\/a>, or occupancy arrangements. It is important to note that registered office addresses differ from principal places of business, so this change does not necessarily indicate a shift in primary operations or laboratory locations.<\/p>
No information on Revenue<\/a>, Earnings<\/a>, or forward-looking financial guidance accompanied this update. Investors should refer to the company’s latest financial reports, presentations, or separate announcements for insights into PIQ’s financial and commercial status.<\/p>
Proteomics International Laboratories Ltd (ASX:PIQ) is the listed parent entity within the PILL Group. Proteomics International operates as a wholly owned subsidiary and trading name of PIQ. This corporate structure means the registered office change applies to the ASX-listed entity, Proteomics International Laboratories Ltd, which acts as the Holding Company<\/a>.<\/p>
This dual structure — with PIQ as the listed entity and Proteomics International as the operating subsidiary — is common in the medical technology sector. Investors and analysts should note that regulatory disclosures and investor communications are issued under the PIQ ticker, while operational activities and branding may use the Proteomics International name.<\/p>
The immediate effect on PIQ’s share price was not evident from public data. Registered office address changes are typically administrative and not market-moving events, so this update alone is unlikely to significantly affect investor sentiment or trading volumes. Such disclosures are routine and generally do not trigger material share price fluctuations.<\/p>
Investors focused on PIQ’s progress in precision diagnostics and proteomics may find this update of limited immediate impact on their Investment<\/a> thesis. Key upcoming milestones for PIQ investors will likely relate to clinical advancements, commercial deals, revenue growth, or regulatory approvals in the company’s diagnostics pipeline, none of which were mentioned in this notice.<\/p>
Although the company has not explicitly connected the registered office change to any strategic initiatives, relocating the registered address to the Harry Perkins Institute of Medical Research aligns with a medical technology company’s interest in proximity to leading biomedical research infrastructure. The institute is involved in diverse disease research programs and is situated within the Nedlands precinct, close to academic and clinical partners.<\/p>
This announcement indicates that PIQ remains embedded in the same geographic and scientific environment where it has operated. Investors may watch for future disclosures clarifying whether this move accompanies new research collaborations, Facility<\/a> agreements, or operational changes. No such details were provided in the current release.<\/p>
Proteomics International’s Specialisation in Precision Diagnostics and Proteomics<\/h2>
Maintaining Presence in the Nedlands, Western Australia Research Hub<\/h2>
Board Approval and Governance for the Registered Office Update<\/h2>
No Financial or Operational Guidance Provided with the Office Move<\/h2>
Relationship Between PIQ and the PILL Group Structure<\/h2>
Share Price Impact and Investor Outlook Following the Address Change<\/h2>
Potential Implications of the Move to 6 Verdun Street for PIQ’s Operations<\/h2>
